What do systematic reviews say?

Deliberate self‐harm

Adverse event: lead failure/ displacement · adults with chronic pain

Adverse events: need for reoperation/ reimplantation · adults with chronic pain

Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · adults with chronic pain

Adverse event: lead failure/ displacement · adults with chronic pain

Adverse events: infection · adults with chronic pain

Adverse events: need for reoperation/ reimplantation · adults with chronic pain

Adverse events: other · adults with chronic pain

Participant‐reported pain relief of 50% or greater · adults with chronic pain

Adverse events: infection · adults with chronic pain

Adverse events: other · adults with chronic pain

Pain intensity (number of people with ≥ 50% improvement) · adults with chronic pain

Surgical complications, non‐serious (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer

Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Clinical progression · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Quality of life · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)